Drug-specific sites of topoisomerase II DNA cleavage in Drosophila chromatin: Heterogeneous localization and reversibility

Cancer Research

Volumn 56, Issue 8, 1996, Pages 1855-1862

  Borgnetto, Maria E ^a   Zunino, Franco ^a   Tinelli, Stella ^a   Käs, Emmanuel ^a,b   Capranico, Giovanni ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMONAFIDE; AMSACRINE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN DERIVATIVE; SATELLITE DNA; TENIPOSIDE;

ANIMAL CELL; ARTICLE; CELLULAR DISTRIBUTION; CHROMATIN STRUCTURE; DNA CLEAVAGE; DNA REPAIR; DNA STRAND BREAKAGE; GENE CLUSTER; GENE LOCUS; GENOME; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SEQUENCE ANALYSIS; SOUTHERN BLOTTING;

AMSACRINE; ANIMALS; BASE SEQUENCE; BINDING SITES; CELL LINE; CHROMATIN; DNA; DNA PRIMERS; DNA TOPOISOMERASES, TYPE II; DNA, SATELLITE; DOXORUBICIN; DROSOPHILA MELANOGASTER; ENZYME INHIBITORS; GENES, INSECT; HISTONES; KINETICS; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS (GENETICS); SUBSTRATE SPECIFICITY; TENIPOSIDE;

EID: 0029922061     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Laemmli, U. K. Käs, E., Poljak, L., and Adachi, Y. Scaffold-associated regions. cis-acting determinants of chromatin structural loops and functional domains. Curr. Opin. Gen. Dev , 2. 275-285, 1992.
2. Roberge, M , and Gasser, S. M DNA loops: structural and functional properties of scaffold-attached regions. Mol. Microbiol., 6: 419-423, 1992.
3. Wang, J C. DNA topoisomerases. Annu. Rev. Biochem., 54. 665-697, 1985.
4. Liu, L F., and Wang, J. C. Supercoiling of the DNA template during transcription. Proc. Natl Acad. Sci. USA. 84: 7024-7027, 1987
5. DiNardo, S., Voelkel, K., and Sternglanz, R DNA topoisomerase II mutant of Saccharomyces cerevisiae, topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication. Proc Natl Acad. Sci. USA, 81: 2616-2620, 1984.
6. Holm, C., Goto, T., Wang, J. C . and Bolstein, D DNA topoisomerase II is required at the time of mitosis in yeast Cell. 41. 553-563, 1985.
7. Pommier, Y., and Kohn, K. W Topoisomerase II inhibition by antitumor intercalators and demethylepipodophyllotoxins. In: R I. Glazer (ed). Developments in Cancer Chemotherapy. pp 175-195. Boca Raton, FL: CRC Press, 1989
8. Liu, L F DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem , 58. 351-375, 1989.
9. Capranico, G., and Zunino, F DNA topoisomerase-trapping antitumour drugs. Eur. J. Cancer, 28A: 2055-2060, 1992
10. Gasser, S. M., and Laemmli, U. K The organisation of chromatin loops characterization of a scaffold attachment site. EMBO J., 5: 511-518, 1986
11. Earnshaw, W C., and Heck, M M Localization of topoisomerase II in mitotic chromosomes. J. Cell Biol., 100: 1716-1725, 1985
12. Pommier, Y , Cockerill, P. N , Kohn, K W., and Garrard, W. T. Identification within the simian virus 40 genome of a chromosomal loop attachment site that contains topoisomerase II cleavage sites J Virol , 64: 419-423, 1990.
13. Adachi, Y., Käs, E , and Laemmli, U K Preferential, cooperative binding of DNA topoisomerase II to scaffold-associated regions. EMBO J , 8: 3997-4006, 1989.
14. Gromova, I. I., Thomsen, B , and Razin, S V. Different topoisomerase II antitumor drugs direct similar specific long-range fragmentation of an amplified c-MYC gene locus in living cells and in high-salt-extracted nuclei. Proc. Natl. Acad. Sci USA, 92: 102-106, 1995.
15. Udvardy, A , and Schedl, P The dynamics of chromatin condensation, redistribution of topoisomerase II in the 87A7 heat shock locus during induction and recovery Mol. Cell Biol., 13 7522-7530, 1993
16. Udvardy, A., and Schedl, P. Chromatin structure, not DNA sequence specificity, is the primary determinant of topoisomerase II sites of action in vivo Mol Cell Biol., 11 4973-4984, 1991.
17. Muller, M T , and Mehta, V. B. DNase I hypersensitivity is independent of endogenous topoisomerase II activity during chicken erythrocyte differentiation. Mol. Cell. Bio., 8: 3661-3669, 1988.
18. Reitman, M., and Felsenfeld, G. Developmental regulation of topoisomerase II sites and D.Nase I-hypersensitive sites in the chicken β-globin locus. Mol Cell Biol., 10. 2774-2786, 1990.
19. Kas, E , and Laemmli, U K In vivo topoisomerase II cleavage of the Drosophila histone and satellite III repeats DNA sequence and structural characteristics EMBO J. 11: 705-716, 1992
20. Yang, L., Rowe, T. C., and Liu, L F. Identification of DNA topoisomerase II as an intracellular target of antitumor epipodophyllotoxins in simian virus 40-infected monkey cells Cancer Res., 45. 5872-5876, 1985.
21. Cullinan, E. B., and Beerman, T. A. A study of drug-induced topoisomerase II-mediated DNA lesions on episomal chromatin J. Biol. Chem., 264; 16268-16275, 1989.
22. Pommier, Y., Orr, A., Kohn, K. W., and Riou, J. F. Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene. Cancer Res., 52: 3125-3130, 1992.
23. Pommier, Y., Capranico, G., Orr, A., and Kohn, K. W. Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide [erratum in Nucleic Acids Res., 19, 7003, 1991]. Nucleic Acids Res , 19 5973-5980, 1991.
24. Bigioni, M , Zunino, F., and Capranico, G. Base mutational analysis of topoisomerase II-idarubicin-DNA ternary complex formation Evidence for enzyme subunit cooperativity in DNA cleavage. Nucleic Acids Res., 22: 2274-2281, 1994.
25. Capranico, G., Supino, R., Binaschi, M., Capolongo, L., Grandi, M , Suarato, A., and Zunino, F. Influence of structural modifications at the 3′ and 4′ positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance. Mol. Pharmacol., 45: 908-915, 1994
26. De Isabella, P., Zunino, F., and Capranico, G. Base sequence determinants of amonafide stimulation of topoisomerase II DNA cleavage. Nucleic Acids Res , 23. 223-229, 1995.
27. Pommier, Y., Kohn, K. W., Capranico, G., and Jaxel, C. Base sequence selectivity of topoisomerase inhibitors suggests a common model for drug action. In: T. Andoh, H. Ikeda, and M. Oguro (eds), Molecular Biology of DNA Topoisomerases and Its Application to Chemotherapy, pp. 215-227 Boca Raton, FL: CRC Press, 1993
28. Freudenreich, C. H. and Kreuzer, K. N. Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex. Proc. Natl. Acad. Sci. USA, 91-11007-11011, 1994.
29. Sambrook, I, Fritsch, E F, and Maniatis, T. Molecular Cloning. A Laboratory Manual, pp. 9.31-9.57 Cold Spring Harbor, NY Cold Spring Harbor Laboratory, 1989.
30. 3 satellite DNA of Drosophlia melanogaster. J Mol Biol., 135: 465-481, 1979.
31. Saluz, H , and Jost, J-P. A simple high-resolution procedure to study DNA methylation and in vivo DNA-protein interactions on a single-copy gene level in higher eukaryotes Proc. Natl. Acad. Sci USA, 86 2602-2606, 1989.
32. Kohn, K. W. Principles and practice of DNA filter elution. Pharmacol. & Ther., 49: 55-77, 1991.
33. Binaschi, M , Capranico, G., De Isabella, P , Mariani, M., Supino, R., Tinelli, S., and Zunino, F. Comparison of DNA cleavage induced by etoposide and doxorubicin in two human small-cell lung cancer lines with different sensitivities to topoisomerase II inhibitors. Int. J. Cancer, 45: 347-352, 1990
34. Kas, E., Poljak, L., Adachi, Y , and Laemmli, U K A model for chromatin opening: stimulation of topoisomerase II and restriction enzyme cleavage of chromatin by distamycin EMBO J., 12: 115-126, 1993.
35. Worcel, A , Gargiulo, G., Jesee, B , Udvardy, A., Louis, C., and Schedl, P. Chromatin fine structure of the histone gene complex of Drosophila melanogaster. Nucleic Acids Res., 11: 421-439, 1983.
36. Capranico, G., Jaxel, C , Roberge, M , Kohn, K W., and Pommier, Y. Nucleosome positioning as a critical determinant for the DNA cleavage sites of mammalian DNA topoisomerase II in reconstituted simian virus 40 chromatin. Nucleic Acids Res , 18: 4553-4559, 1990
37. Clark, J. M. Novel non-templated nucleotide addition reactions catalyzed by procaryotic and eucaryotic DNA polymerases. Nucleic Acids Res , 16: 9677-9686. 1988
38. Hu, G. DNA polymerase-catalyzed addition of nontemplated extra nucleotides to the 3′ end of a DNA fragment DNA Cell Biol , 12: 763-770, 1993.
39. Brou, C., Kuhn, A , Staub, A., Chaudhary, S , Grummt, I., Davidson, I., and Tora, L. Sequence-specific transacuvators counteract topoisomerase 11-mediated inhibition of in vitro transcription by RNA polymerases I and II. Nucleic Acids Res , 21: 4011-4018, 1993
40. Roca, J., Berger, J M , and Wang, J. C. On the simultaneous binding of eukaryotic DNA topoisomerase II to a pair of double-stranded DNA helices. J. Biol Chem., 268, 14250-14255, 1993.
41. Zunino, F., and Capranico, G DNA topoisomerase II as the primary target of anti-tumor anthracyclines, Anti-Cancer Drug Design, 5. 307-317, 1990.
42. Hentschel, C C , and Birnstiel, M. L The organization and expression of histone gene families Cell, 25: 301-313, 1981.
43. Bunch, R T., Povirk, L. F., Orr, M S , Randolph, J. K , Fornari, F. A , and Gewirtz, D. A. Influence of amsacrine (m-AMSA) on bulk and gene-specific DNA damage and c-myc expression in MCF-7 breast tumor cells Biochem. Pharmacol , 47. 317-329, 1994.